BlueSignum Corp. – Trademark Portfolio
Entity Type: 03
BlueSignum Corp. holds 14 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 8 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 2 trademarks are registered and 7 are pending. Notable registered marks include MOODEE and DAILYBEAN. The owner is based in Seoul.
1690 Nambusunhwan-ro, Gwanak-gu
7th floor
Seoul 08782 , KR
Showing of trademarks Trademarks
Trademark Classifications
BlueSignum Corp.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Education; providing of training; entertainment; sporting and cultural activities
Frequently Asked Questions
How many trademarks does BlueSignum Corp. have?
BlueSignum Corp. has 14 U.S. trademarks filed with the USPTO. Of these, 2 registered, 7 pending, 5 abandoned.
What trademark classes does BlueSignum Corp. file in?
BlueSignum Corp. files trademarks across 3 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 44 (Medical Services), Class 41 (Education & Entertainment). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are BlueSignum Corp.'s most well-known trademarks?
BlueSignum Corp.'s registered trademark portfolio includes well-known marks such as MOODEE and DAILYBEAN. These are among 2 currently registered trademarks in the portfolio.
What is BlueSignum Corp.'s trademark registration success rate?
BlueSignum Corp. has a 29% trademark registration rate, with 2 out of 7 resolved applications resulting in successful registration. Currently, 7 applications are pending review.